These findings collectively identify CKS2 as a central oncogenic driver in MM pathogenesis and a promising therapeutic target, with its regulatory network involving both upstream TXN modulation and downstream PTEN/AKT/mTOR signaling cascades. This evidence concerns the gene CKS2 and Miyoshi myopathy.